These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Kessler RE, Bies M, Buck RE, Chisholm DR, Pursiano TA, Tsai YH, Misiek M, Price KE, Leitner F. Antimicrob Agents Chemother; 1985 Feb; 27(2):207-16. PubMed ID: 3885849 [Abstract] [Full Text] [Related]
4. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa. van Klingeren B. J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171 [Abstract] [Full Text] [Related]
8. Biological activity of BO-1236, a new antipseudomonal cephalosporin. Nakagawa S, Sanada M, Matsuda K, Hazumi N, Tanaka N. Antimicrob Agents Chemother; 1987 Jul; 31(7):1100-5. PubMed ID: 3116919 [Abstract] [Full Text] [Related]
9. In vitro antimicrobial activity of a novel aminothiazolylglycylcephalosporin, MT0703S, compared with that of ceftazidime, cefoperazone and aztreonam. Okamoto R, Hara T, Yoshida T, Orikasa Y, Ogino H, Iwamatsu K, Inouye S. Drugs Exp Clin Res; 1990 Jul; 16(4):157-65. PubMed ID: 2127567 [Abstract] [Full Text] [Related]
10. In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime. Oizumi K, Hayashi I, Aonuma S, Konno K. Drugs; 1988 Jul; 35 Suppl 2():57-61. PubMed ID: 3135170 [Abstract] [Full Text] [Related]
12. The in-vitro activity of three anti-pseudomonal cephalosporins against isolates from patients with cystic fibrosis. Kelly N, Falkiner FR, Keane CT, Murphy M, Fitzgerald MX. J Antimicrob Chemother; 1981 Sep; 8 Suppl B():175-8. PubMed ID: 19802982 [Abstract] [Full Text] [Related]
13. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Masuyoshi S, Hiraoka M, Inoue M, Tomatsu K, Hirano M, Mitsuhashi S. Drugs Exp Clin Res; 1989 Sep; 15(1):1-10. PubMed ID: 2663406 [Abstract] [Full Text] [Related]
14. Development of bacterial resistance to the third generation cephalosporins and their clinical use. Kolár M, Látal T, Hájek V. J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127 [Abstract] [Full Text] [Related]
15. In vitro activity of ceftazidime and ceftriaxone. Keenholtz SL, Jacobus NV, Tally FP, Gorbach SL. Clin Ther; 1983 Aug; 5(6):603-16. PubMed ID: 6313195 [Abstract] [Full Text] [Related]
16. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains]. Mascellino MT, Prignano G, Iegri F, Lorenzi A. Boll Ist Sieroter Milan; 1982 Aug; 61(4):309-19. PubMed ID: 6100234 [Abstract] [Full Text] [Related]
18. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime. Fung-Tomc J, Huczko E, Pearce M, Kessler RE. Antimicrob Agents Chemother; 1988 Sep; 32(9):1443-5. PubMed ID: 3143306 [Abstract] [Full Text] [Related]